Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/Refractory Pediatric H3 K27M Gliomas

NCT03416530 is registered in ClinicalTrials.gov with Jazz Pharmaceuticals as lead sponsor.

NCT NCT03416530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03416530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/Refractory Pediatric H3 K27M Gliomas
Lead sponsor
Jazz Pharmaceuticals
Phase
Phase 1
Overall status
Terminated
Start date
January 25, 2018
Completion date
May 24, 2023
Enrollment
134 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse intrinsic pontine glioma, glioma, malignant